Trial is evaluating ciforadenant as a potential first line therapy for metastatic renal cell cancer (RCC) in combination with ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) Interim data shows ...

- Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to be presented in a poster session at the American Society of Clinical ...

AEMD CMO will present data on Hemopurifier potential in Long Covid at Keystone Symposium We met virtually with medical therapeutic company Aethlon Medical (NASDAQ:AEMD) this week and present our ...

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research ...

SAN DIEGO, Oct. 21, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies ...

Molecular Partners (MOLN) and Orano Med announced the oral presentation of the latest preclinical data supporting MP0712 as a Radio-DARPin Therapeutic, or RDT, at the European Assocation of Nuclear ...

Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) ...

GBM CTC isolation only possible with Parsortix label-free methodology Data presented at the 7 th ACTC meeting GUILDFORD, SURREY / ACCESS Newswire / September 29, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY ...

Oral presentation of investigator-sponsored study of avutometinib plus defactinib in gynecologic mesonephric cancer, a rare grouping of cancers that generally harbor KRAS mutations BOSTON--(BUSINESS ...

The regional agency asked for the research to be undertaken aas the prospect of local projects have become a hot button issue.